Post-COVID-19 syndrome (anxiety depression and cognitive dysfunction) Post-COVID-19 syndrome, Long COVID, depression, anxiety and insomnia, cognitive decline and brain fog, chronic fatigue
Conditions
Sponsors
Ohsawa Ryota
Noda Yoshihiro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Individuals who were infected with COVID-19 and tested positive by PCR test, etc., and subsequently became negative 2) Individuals who met the diagnostic criteria for depression or anxiety disorder in the DSM-5 for the first time after COVID-19 infection 3) Individuals with severity of 15 or more points on the MADRS 4) Individuals who are deemed capable of giving written consent by the physician in charge 5) Individuals between the ages of 18 and 70 at the time of obtaining consent 6) Individuals who can regularly visit the institution during the period of TMS therapy
Exclusion criteria
Exclusion criteria: 1) Individuals with cerebral organic diseases (e.g., intracranial organic lesions of moderate severity or higher, neurodegenerative diseases, etc.) 2) Individuals with primary sleep disorders (sleep apnea, narcolepsy, etc.) 3) Individuals with a diagnosis of bipolar disorder, schizophrenia, psychotic depression, or substance abuse/dependence 4) Individuals diagnosed with autoimmune or endocrine-metabolic diseases (hypopituitarism, adrenal insufficiency, thyroid disease, diabetes mellitus, etc.) 5) Individuals with a history of convulsive seizures or epilepsy 6) Individuals with serious or unstable physical illnesses that make it difficult for them to receive outpatient TMS therapy 7) Individuals who have received ECT within the past 6 months 8) Individuals who are pregnant 9) Individuals with contraindications to TMS, such as metallic objects in the head and neck region or cardiac pacemakers 10) Individuals deemed inappropriate by the principal investigator or co-investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in HAMD-21 score before and after the novel TMS treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in the following items before and after the novel TMS therapeutic intervention - MADRS - BSI-anxiety - BSS - PSQI - GAF - Q-LES-Q - TMT - LNST - SNST - EXIT25 | — |
Contacts
Public ContactYoshihiro Noda
Shinjuku-Yoyogi Mental Lab Clinic
Outcome results
None listed